National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Candesartan

Synonyms

Candesartan

CANDESARTAN

2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid

Definitions

A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65284

CAS_Registry

139481-59-7

CHEBI_ID

CHEBI:3347

Chemical_Formula

C24H20N6O3

code

C65284

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

Contributing_Source

FDA

DEFINITION

A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.

FDA_UNII_Code

S8Q36MD2XX

FULL_SYN

Candesartan

CANDESARTAN

2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid

label

Candesartan

Legacy Concept Name

Candesartan

Preferred_Name

Candesartan

prefixIRI

Thesaurus:C65284

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C0717550

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C66930

Delete Subject Author Type Created
No notes to display
Create mapping

Delete Mapping To Ontology Source
http://purl.obolibrary.org/obo/CHEBI_3347 GO-PLUS LOOM
http://purl.obolibrary.org/obo/XCO_0000438 XCO LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 EFO LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 CHEBI LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 OBA LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#45145 OCHV LOOM
http://purl.bioontology.org/ontology/ATC/C09CA06 ATC LOOM
http://purl.jp/bio/4/id/200906018066411519 IOBC LOOM
http://purl.bioontology.org/ontology/VANDF/4021151 VANDF LOOM
http://purl.bioontology.org/ontology/RXNORM/214354 NLMVS LOOM
http://purl.bioontology.org/ontology/RXNORM/214354 RXNORM LOOM
http://purl.obolibrary.org/obo/NCIT_C65284 BERO LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000148603 NDFRT LOOM
http://bmi.utah.edu/ontologies/hfontology/C0717550 HFO LOOM
http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000148603 OCVDAE LOOM
http://purl.bioontology.org/ontology/NDDF/007275 NDDF LOOM
http://stirdf.jst.go.jp/id/200907073405862970 IOBC LOOM
http://purl.bioontology.org/ontology/MESH/C081643 MESH LOOM
http://www.drugbank.ca/drugs/DB00796 FTC LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 PDRO LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 DINTO LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 BERO LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 BIOMODELS LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 DRON LOOM
http://purl.obolibrary.org/obo/CHEBI_3347 NIFSTD LOOM
https://go.drugbank.com/drugs/DB13919 MDM LOOM
http://www.phoc.org.cn/pmo/class/PMO_00025467 PMAPP-PMO LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#C081643 RH-MESH LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/372512008 SNOMEDCT LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#C0717550 OCHV LOOM
http://purl.bioontology.org/ontology/LNC/LP171390-0 LOINC LOOM